Why the study?
Advances in cardiac amyloidosis diagnosis and treatment have extended life expectancy, but managing increasingly heterogeneous patients and challenging clinical scenarios involves many unexplored grey areas.
What are the practical suggestions for managing challenging clinical scenarios in patients with cardiac amyloidosis?
What are the practical suggestions for managing challenging clinical scenarios in patients with cardiac amyloidosis?
This review provides practical suggestions for managing complex clinical scenarios in patients with cardiac amyloidosis, such as heart failure medication, atrial fibrillation, and device therapy.
Answers are grounded in this paper and cite their sources.
May inform HF, AF, and device strategies in cardiac amyloidosis; leaves open need for prospective validation.
Recent advances in the diagnosis and treatment of cardiac amyloidosis (CA) have translated into a longer life expectancy of patients and more challenging clinical scenarios. Compared to the past, patients with CA and heart failure (HF) currently encountered in clinical practice are a more heterogeneous population and require tailored strategies. The perception of CA as a treatable disease has opened new possibilities for the management of these patients, but many grey areas remain to be explored. The aim of this review is to provide practical suggestions for daily clinical activity in the management of challenging scenarios in CA, including the effectiveness and tolerability of evidence-based HF medication; rate vs. rhythm control in atrial fibrillation, thromboembolic risk, and anticoagulation therapies; replacement of severe aortic valve stenosis; the impact of implantable cardioverter defibrillator on survival; and the usefulness of cardiac resynchronization therapy.
No takes yet. Share an insight, caveat, or question.
Porcari et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: